Phase III study of Phlai capsules in the treatment of allergic rhinitis: A randomized, double-blind, placebo-controlled trial.
Hoang, Seresirikachorn, Chitsuthipakorn, et al. Asian Pacific journal of allergy and immunology, 2026.
Study design: Phase 3 double-blind, placebo-controlled randomized clinical trial in 262 patients with allergic rhinitis. Plai capsules at 100 mg or 200 mg once daily for 4 weeks.
- Plai 100 mg improved the total score of five nasal symptoms compared with placebo (difference -0.62).
- Runny nose, nasal itching, and eye itching improved slightly at week 4.
- Nasal congestion, sneezing, and quality of life scores did not improve significantly.
- The 200 mg dose gave no added benefit, and side effects were comparable between groups.
What it means for your product: The strongest oral clinical evidence for bangle. The effect is small, so it suits education for seasonal comfort products, not allergy treatment claims.









